Advertisement

Topics

Ionis Licenses Novel Antisense Drug for the Treatment of Centronuclear Myopathy to Dynacure

19:00 EST 8 Nov 2017 | BioSpace

Ionis earns $5 million license fee from Dynacure.

Original Article: Ionis Licenses Novel Antisense Drug for the Treatment of Centronuclear Myopathy to Dynacure

NEXT ARTICLE

More From BioPortfolio on "Ionis Licenses Novel Antisense Drug for the Treatment of Centronuclear Myopathy to Dynacure"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...